International Stem Cell Corporation Announces Second Patient with Parkinson’s Disease Treated in Phase I Clinical Trial
International Stem Cell Corporation to Present Results of Neural Stem Cell Transplantation for Parkinson’s Disease
International Stem Cell Corporation and Rohto Pharmaceutical Enter Second Stage of Research Agreement
Alvopetro Announces Q3 2026 Dividend of US$0.12 Per Share and Supplementary Information on December 31, 2025 Prospective Resources
Skyharbour Partner Company Purecore Commences Data Compilation and Target Generation at The Yurchison Uranium Property
